Related Experiment Videos

A new approach to therapy for hepatocellular carcinoma?

Stephen A Harrison¹, Adrian M Di Bisceglie

¹Saint Louis University, MO, USA.

Hepatology (Baltimore, Md.)

|January 24, 2003

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert Consensus.

Drug safety·2025

Novel Viral Sequences in a Patient with Cryptogenic Liver Cirrhosis Revealed by Serum Virome Sequencing.

Viruses·2025

HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study.

Clinical and molecular hepatology·2025

Challenges in Histological Endpoints for MASH Therapies: An Exercise in Statistical Modelling.

Alimentary pharmacology & therapeutics·2025

Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial.

The lancet. Gastroenterology & hepatology·2024

acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2024

See all related articles